Document is current
Any future updates will be listed below
-
Authors
Anglicheau, Dany https://orcid.org/0000-0001-5793-6174
Durrbach, Antoine https://orcid.org/0000-0003-0385-8726
Bardoulat, Isabelle
Arnaud, Mickael
Cotté, François-Emery https://orcid.org/0000-0002-6758-4552
Vadanici, Radu
Chartier, Mélanie https://orcid.org/0000-0003-2469-920X
Glotz, Denis https://orcid.org/0000-0001-5258-4237
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb
- License Information
-
More Information
Article History
Received: 17 March 2025
Accepted: 6 April 2025
First Online: 13 May 2025
Declarations
:
: DA has received consultancy fees from Astellas, Astra Zeneca, BMS and Chiesi. AD and DG received consultancy fees from BMS in the context of the present study. FEC, RV and MC are employees of Bristol-Myers Squibb, the study sponsor. IB and MA are employees of IQVIA, a contract research organization that received funding from the sponsor for the operational management of the study and for data analysis.
: The study was conducted in accordance with International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP) and applicable regulatory requirements. The study protocol was submitted and approved by the relevant ethical committee for this type of database study ( Comité Éthique et Scientifique pour les Recherches, les Études et les Évaluations dans le domaine de la Santé ; CESREES). Approval was obtained from the French data protection agency ( Commission Nationale de l'Informatique et des Libertés ; CNIL) with respect to the confidentiality of individual patient data.
: All procedures involving human participants adhered to the required ethical standards, and no animal studies were involved.
: Not applicable. The study was performed on a pseudoanonymized database.
